Comprehensive Defensin Assay for Saliva

Citations Over TimeTop 12% of 2008 papers

Abstract

Defensins are highly basic cationic peptides that are important components of the innate and adaptive immune response pathways. In addition, these peptides are involved in CD8+ T cell response to HIV-1, increased pulmonary infection risk among cystic fibrosis patients, upregulated levels of HNP-5 for patients with ulcerative colitis and Crohn's disease, and monitoring HNP-3 levels as a tumor classification scheme for cutaneous T cell lymphomas, and have promise in the pharmaceutical field as a new class of antibiotics. Here we present a parallel assay for the alpha (HNP1-3) and beta (HBD1-2) classes of defensins in saliva that are naturally observed in the concentration range of 1 ng/mL to 10 microg/mL. The method utilizes solid phase extraction of saliva samples combined with liquid chromatography-tandem mass spectrometry to identify and quantitate defensin targets. The approach involves limited sample manipulation and is easily amenable to automation. The saliva samples analyzed are derived from a large cohort study focused on examining the role of polymorphisms in genes of innate and adaptive immunity in modulating the response to vaccination for two gastrointestinal tract infections: typhoid and cholera. The alpha-defensin levels observed range from 1 to 10 microg/mL and correlate well with known active concentrations against a wide variety of pathogens. The observed concentration range for beta-defensins was between the detection limit and 33 ng/mL and had a sensitivity level that was comparable to immunoassay-based detection. This method is easily adapted for use in a clinical immunology setting and can be modified for other biological matrixes. This assay will facilitate examination of the production, secretion, and regulation of defensin peptides in a direct fashion to coordinate levels of these compounds with gender, age, response to vaccination, gene copy number, and oral health.

Related Papers

• → Cyclic Peptides as Novel Therapeutic Microbicides: Engineering of Human Defensin Mimetics(2017)93 cited
• → Dysregulation of human beta-defensin-3 expression in the peripheral blood of patients with sepsis(2021)5 cited
• → Differential expression of α‐ and β‐defensins in human peripheral blood(2003)76 cited
• → Mouse beta defensin-1 is a functional homolog of human beta defensin-1(1998)86 cited
• HUMAN DEFENSIN PEPTIDES WITH ANTIMICROBIAL PROPERTIES: AN OVERVIEW(2012)